[Milnacipran (ixel) in the treatment of anxiodepressive and sexual disorders in patients with noninflammatory syndrome of chronic pelvic pain].
Psychoemotional disorders were studied in 57 patients aged 26-44 years (mean age 36.2 +/- 6.9 years) with noninflammatory chronic pelvic pain syndrome (CPPS). The disease duration varied from 1 to 5 years. Pain syndrome, anxiety, depression, sexual disorders were assessed by Visual Analogue Scale, Spilberger's Scale, Beck's Scale, International Index of Erectile Function, respectively. All the patients received milnacipran in a daily dose 100 mg. The effect was assessed in 54 patients. Pain syndrome regressed moderately (by 26.1%). The degree of anxiety, depression and sexual disorders diminished to mild. Thus, milnacipran (ixel) demonstrated its efficacy in the treatment of anxiodepressive disorders and psychogenic erectile dysfunction in patients with noninflammatory CPPS.
G V
GV
Selitskiĭ
A D
AD
Kaprin
S B
SB
Izvozchikov
A V
AV
Bolotov
A V
AV
Troshina
D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001007:Anxiety / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D003521:Cyclopropanes / Q000008:administration & dosage / Q000627:therapeutic use*; D003863:Depression / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008297:Male; D000078764:Milnacipran; D017699:Pelvic Pain / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D000928:Antidepressive Agents; D003521:Cyclopropanes; D000078764:Milnacipran